BioCentury
ARTICLE | Company News

Alkermes discontinues pain candidate, reports earnings

February 25, 2015 3:03 AM UTC

Alkermes plc (NASDAQ:ALKS) dipped $3 to $70.64 on Tuesday after it discontinued development of pain candidate ALKS 7106 and reported 4Q14 earnings.

The company said results from a Phase I trial of ALKS 7106 did not meet the company's pre-specified criteria for advancing into Phase II. Alkermes plans to develop backup pain candidates. ...